CAPTOR-BC: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
Latest Information Update: 20 Apr 2023
Price :
$35 *
At a glance
- Drugs Ribociclib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms CAPTOR-BC
- 20 Apr 2023 Last checked against ClinicalTrials.gov record.
- 25 Jan 2023 Planned End Date changed from 1 Aug 2026 to 1 Oct 2026.
- 25 Jan 2023 Planned primary completion date changed from 1 Aug 2024 to 1 Oct 2024.